

# **Report of the 2014 USAHA Bovine Tuberculosis Scientific Advisory Subcommittee**

Kansas City, Kansas

October 20, 2014

# Presentations

## **Integration of Models and Dense Phylogenetic Sampling to Understand BTB epidemiology in Cattle and Wildlife**

Professor Rowland Kao, Institute of Biodiversity Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.

## **Effect of Skin Test on Serum Antibody Responses to *Mycobacterium bovis* Infection in Cattle**

Ray Waters<sup>1</sup>, Jeff Nelson<sup>2</sup>, Tyler Thacker<sup>1</sup>, Mayara Maggioli<sup>1</sup>, Molly Stafne<sup>3</sup>, Kristin Bass<sup>4</sup>, Rick Linscott<sup>5</sup>, John Lawrence<sup>5</sup>, and Mitch Palmer<sup>1</sup>

<sup>1</sup>National Animal Disease Center, ARS, USDA, Ames, Iowa

<sup>2</sup>National Veterinary Services Laboratories, VS, APHIS, USDA, Ames, Iowa

<sup>3</sup>Iowa State University, College of Veterinary Medicine, Ames, Iowa

<sup>4</sup>Bethyl Laboratories, Montgomery, Texas

<sup>5</sup>IDEXX Laboratories, Westbrook, Maine

# Presentations

**Comparison of CSL and Lelystad PPD in the Bovigam under field trial conditions in the US-** Dr. Bjoern Schroeder, Thermo Fisher Scientific, Prionics AG, Schlieren-Zurich, Switzerland.

**Distribution of *Mycobacterium bovis* genotypes in infected deer and the implication for whole genome sequencing epidemiology**

Tyler C Thacker<sup>1</sup>, Mitchell V. Palmer<sup>1</sup>, Suelee Robbe-Austerman<sup>2</sup>, Tod P. Stuber<sup>2</sup>, W. Ray Waters<sup>1</sup>

<sup>1</sup>National Animal Disease Center, ARS, USDA, Ames, Iowa

<sup>2</sup>National Veterinary Services Laboratories, VS, APHIS, USDA, Ames, Iowa

**Update on the NVSL bTB serum bank and use of Chembio DPP in captive cervids-** Dr. Jeff Nelson, USDA, APHIS, National Veterinary Services Laboratories, Ames, IA, USA.

# Use of the Chembio Dual Path Platform (DPP) VetTB Assay<sup>®</sup> as a primary test

**Request-** Comment on the use of the Dual Path Platform (DPP) VetTB Assay<sup>®</sup> as a stand-alone primary and secondary test for *Mycobacterium bovis* (bTB) in cervids.

**Question-** Is it scientifically valid to change the Cervid TB serological testing protocol at NVSL by eliminating the CervidTB Stat-Pak<sup>®</sup> as the primary test and instituting the use of the DPP VetTB Assay<sup>®</sup> as the primary serological test and also using the DPP VetTB Assay<sup>®</sup> as the confirmatory test 30 days after the initial positive serological test?

# TB SAS Comments

1. As Chembio will discontinue the manufacture of the CervidTB Stat-Pak<sup>®</sup>, a change in protocol is requisite. Replacing a subjective, visually interpreted assay with an objective assay that uses electronically determined, numeric values for status classification is considered a positive change.
1. From a regulatory perspective, terminology may be important; therefore, categorizing the second DPP as a “repeat test” is more accurate than using terminology such as “confirmatory test”.

# TB SAS Comments

3. It appears that the DPP does not categorize as positive, samples categorized as negative by the Stat-Pak.

This conclusion is based on a sample size determined to be statistically valid by a CVB statistician (i.e. 150 samples each of the two most commonly tested species). This is the basis of the critical assumption that 8285 Stat-Pak negative samples would have also been DPP negative if tested, thus yielding the specificities of 99.76% for the 1<sup>st</sup> DPP and 99.89% for the 2<sup>nd</sup> DPP.

Presuming this assumption is valid; it appears scientifically acceptable to make the proposed change in the Cervid TB testing protocol.

# Use of Lelystad PPD in Bovigam<sup>®</sup>

**Request-**Comment on data from 2012 and 2014 on comparison of PPD from 2 different sources (CSL and Lelystad) in order to demonstrate equivalence of product performance. This was done to fulfill requirements for approval of the Bovigam<sup>®</sup> kit containing Lelystad PPD in place of CSL PPD.

**Question-** Can Lelystad PPD be used in place of current CSL PPD in the Bovigam<sup>®</sup> without compromising test sensitivity or specificity?

# TB SAS Comments

The 2014 submission provides side-by-side comparisons of Lelystad and CSL PPDs using samples from confirmed *M. bovis* infected cattle (confirmation by culture or PCR) from herds in Michigan and Colorado, and presumed non-infected herds in Texas, Idaho, Minnesota and Pennsylvania. Data from a total of 84 confirmed *M. bovis* infected animals and 711 non-infected animals are presented.

Bovigam<sup>®</sup> sensitivity was 73.8% for Lelystad PPD and 45.2% for CSL PPD, Bovigam<sup>®</sup> specificity was 96.9% for Lelystad PPD and 95.1% for CSL PPD

2014 data, combined with that reviewed in 2012, demonstrates that Lelystad PPD performs with superior sensitivity and equivalent specificity to CSL PPD in the Bovigam<sup>®</sup> assay. It is the opinion of the TB SAS that approval of Lelystad PPD for use in the Bovigam<sup>®</sup> assay would be appropriate.